Download PDF
Thromb Haemost 1974; 32(02/03): 600-607
DOI: 10.1055/s-0038-1647729
Original Article
Schattauer GmbH

Intrinsic Activation of Prothrombin Potentiated by Celite and Reduced by Kaolin[*]

E. P Kang
1   American National Red Cross Blood Research Laboratory, Bethesda, Maryland 20014 and Department of Physiology and Biophysics Georgetown University School of Medicine, Washington, D. C. 20007
,
D. C Triantaphyllopoulos
1   American National Red Cross Blood Research Laboratory, Bethesda, Maryland 20014 and Department of Physiology and Biophysics Georgetown University School of Medicine, Washington, D. C. 20007
› Author Affiliations
Further Information

Publication History

Received 01 July 1974

Accepted 05 August 1974

Publication Date:
30 June 2018 (online)

    Permissions and Reprints

Summary

Preparations of human prothrombin complex were absorbed with celite or kaolin and the 10% sodium chloride eluate of both absorbents was tested for its effectiveness to correct the prolonged partial thromboplastin time of celite-exhausted plasma. Both types of eluate were effective, indicating the presence of contact factors in the prothrombin preparations. Activation of the absorbed prothrombin complexes via the intrinsic pathway showed that while the kaolin absorbed preparations generated less thrombin than the parent solutions, celite absorbed complexes generated more thrombin than before they were absorbed. Both types of absorbed preparations generated the same amount of thrombin as before absorption when they were activated via the extrinsic pathway. When the absorption of the contact factors was performed by the addition of celite in the plasma before the purification of the prothrombin complex, the prothrombin preparations obtained generated less thrombin via the intrinsic pathway than the preparations which were obtained from plasma which had not been treated with celite.

* Contribution No. 293 from the American National Red Cross Blood Research Laboratory. Presented in part at the 58th Annual Meeting of the Federation of American Societies for Experimental Biology


 

  • References

  • 1 Aronson D. L, Mustafa A. M, Mushinski J. F. 1969; Purification of human factor X and comparison of peptide maps of human factor X and prothrombin. Biochimica et Biophysica Acta 188: 25.
    CrossrefPubMedGoogle Scholar
  • 2 Damus P. S, Hick M, Rosenberg R. D. 1973; Anticoagulant action of heparin. Nature 246: 355.
    CrossrefPubMedGoogle Scholar
  • 3 Edson J. R. 1974; Prothrombin complex concentrates and thromboses. New England Journal of Medicine 290: 403.
    CrossrefPubMedGoogle Scholar
  • 4 Forbes C. D, Pensky J, Ratnoff O. D. 1970; Inhibition of activated Hageman Factor and activated plasma thromboplastin antecedent by purified serum C-l inactivator. Journal of Laboratory and Clinical Medicine 76: 809.
    PubMedGoogle Scholar
  • 5 Goldstein R, Zonderman E. B. 1958. Purification of prothrombin and its separation from other coagulation factors. In: Proceedings of the International Congress. International Society of Haematology, II Pensiero Scientifico; Rome: 1958: 1006.
    Google Scholar
  • 6 Iatridis S. G, Iatridis P. G, Ferguson J. H. 1964; Roles of surface factor and a plasma inhibitory activity (anti-SF) during experimental thrombosis in rabbits. Thrombosis et Diathesis Haemorrhagica 12: 480.
    PubMedGoogle Scholar
  • 7 Jacobsson E. 1960; Platelet adhesion and aggregation following contact between blood and vascular catheters in vitro. Scandinavian Journal of Haematology 06: 216.
    PubMedGoogle Scholar
  • 8 Jacobsson B, Nilsson I. M. 1969; Catheter material and blood coagulation studies in vitro. Scandinavian Journal of Haematology 06: 386.
    PubMedGoogle Scholar
  • 9 Kasper C. K. 1973; Postoperative thrombosis in hemophilia B. New England Journal of Medicine 289: 160.
    PubMedGoogle Scholar
  • 10 Kasper C. K. 1974; Prothrombin complex concentrates and thromboses. New England Journal of Medicine 290: 404.
    PubMedGoogle Scholar
  • 11 Marchesi S. L, Burney R. 1974; Prothrombin complex concentrates and thromboses. New England Journal of Medicine 290: 403.
    CrossrefPubMedGoogle Scholar
  • 12 Margolis T. 1957; Initiation of blood coagulation by glass and related surfaces. Journal of Physiology 137: 95.
    CrossrefPubMedGoogle Scholar
  • 13 Niemetz J, Nossel H. L. 1967; Method of purification and properties of anti-XIa (inhibitor of the contact product). Thrombosis et Diathesis Haemorrhagica 17: 335.
    PubMedGoogle Scholar
  • 14 Nossel H. L. 1964. The Contact Phase of Blood Coagulation. Blackwell; Oxford.:
    Google Scholar
  • 15 Quick A. J. 1966. Hemorrhagic Diseases and Thrombosis. Lea and Febiger; Philadelphia: 391.
    Google Scholar
  • 16 Seegers W. H, Landaburu R. H, Fenichel R. L. 1957; Isolation of platelet cofactor I from plasma and some properties of the preparation. American Journal of Physiology 190: 1.
    PubMedGoogle Scholar
  • 17 Schiffman S, Lee P. 1973; Activation of highly purified factor XI. Circulation Supplement 6, abstract 298.
    PubMedGoogle Scholar
  • 18 Soulier J. P, Prou-Wartelle O. 1960; New data on Hageman factor and plasma thromboplastin antecedent: The role of “contact” in the initial phase of blood coagulation. British Journal of Haematology 06: 88.
    CrossrefPubMedGoogle Scholar
  • 19 Triantaphyllopoulos D. C. 1972; Intravascular coagulation following injection of prothrombin complex. American Journal of Clinical Pathology 57: 603.
    CrossrefPubMedGoogle Scholar
  • 20 Tullis J. L, Melin M, Jurigan P. 1965; Clinical use of human prothrombin complexes. New England Journal of Medicine 273: 667.
    CrossrefPubMedGoogle Scholar
  • 21 Ware A. G, Seegers W. H. 1949; Two stage procedure for the quantitative determination of prothrombin concentration. American Journal of Clinical Pathology 19: 471.
    CrossrefPubMedGoogle Scholar
  • 22 Wickerhauser M. 1971; Large scale preparation of factor VIII concentrate from frozen cryoethanol precipitate. Thrombosis et Diathesis Haemorrhagica, Supplement 43: 165.
    PubMedGoogle Scholar
  • 23 Wickerhauser M, Sgouris J. T. 1972; Development of large scale fractionation methods. II. Isolation of factor IX concentrate (prothrombin complex) for clinical use. Vox Sanguinis 22: 137.
    PubMedGoogle Scholar